Actively Recruiting
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2025-11-20
64
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To explore the effectiveness of anlotinib hydrochloride capsule in postoperative non-pCR non-small cell lung cancer patients with adjuvant intensive therapy
CONDITIONS
Official Title
To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily agree to participate and sign informed consent with good compliance
- Age 18 years or older
- Both men and women
- ECOG performance status 0 to 1
- Expected survival of at least 3 months
- Stage IIA to IIIA non-small cell lung cancer (NSCLC)
- Previously received PD-1/PD-L1 inhibitors combined with chemotherapy before surgery
- Underwent complete (R0) surgical removal of lung cancer
- Did not achieve pathological complete response after neoadjuvant therapy
- Time between surgery and first study medication is 4 to 12 weeks
- Good function of main organs
- Women of childbearing potential must use effective contraception during the study and for 6 months after, with negative pregnancy test within 7 days before enrollment
- Men must use effective contraception during the study and for 6 months after
You will not qualify if you...
- History or current diagnosis of other malignant tumors within the past 5 years, except for certain treated cancers with 5-year disease-free survival
- Known genetic abnormalities eligible for targeted therapy (EGFR or ALK tested for non-squamous NSCLC)
- Cardiovascular or cerebrovascular diseases including heart failure, significant heart block, recent myocardial infarction, unstable angina, or serious arrhythmias
- Arteriovenous thrombosis or embolic events within 6 months
- Participation in other drug clinical trials within the last 30 days
- Treatment with specified Chinese patent anti-tumor medicines within 2 weeks before starting study drug
- Major surgery other than lung cancer removal within 4 weeks before starting study drug
- Any other condition deemed by the investigator to make the patient unsuitable for the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Actively Recruiting
Research Team
Z
Zhansheng
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here